Novartis
(https://pluvicto.com) 📸 Data Snapshot: May 30, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Authority is verified through extensive structured data (JSON-LD) that connects the brand to Novartis and provides external validation links to Wikipedia, the FDA, and MedlinePlus. There are no ‘ghost experts’; the site leans on the authority of clinical trials and the Novartis Patient Support team. The technical implementation of schema is comprehensive, covering drug strength, mechanism of action, and price.
There is no disconnect between marketing claims and evidence. The claim of ‘proven results’ is directly linked to the PSMAfore and VISION trials with specific metrics provided. The claim of being available at ‘over 600 treatment centers’ is supported by a functional locator tool, proving the logistical reach claimed by the marketing copy.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
{
"@context": "https://schema.org",
"@type": "Organization",
"@id": "https://us.pluvicto.com/#Organization",
"name": "Novartis",
"url": "https://www.novartis.com/us-en/",
"logo": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/logo.svg",
"description": "Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.",
"makesOffer": {
"@type": "Offer",
"@id": "https://us.pluvicto.com/#makesOffer",
"name": "Pluvicto",
"alternateName": "Lutetium Lu 177 vipivotide tetraxetan",
"availability": "https://schema.org/PrescriptionOnly",
"sameAs": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto"
}
}
/about-pluvicto/how-pluvicto-works/
{
"@context": "https://schema.org",
"@type": "medicalGuideline",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#medicalGuideline",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works",
"name": "Pluvicto's metastatic Castration-Resistant Prostate Cancer (mCRPC) Medical Guideline",
"legalStatus": "Prescription only, FDA approved",
"description": "Learn about metastatic castration-resistant prostate cancer (mCRPC) and how to find out if you are PSMA+. See full Prescribing and Safety Information.",
"guidelineSubject": {
"@type": "drugClass",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#drugClass",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works",
"description": "PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with hormon therapy or hormone therapy and chemotherapy",
"drug": {
"@type": "drug",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#drug",
"image": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/psma617_pluvicto_r_rgb_us-2.jpg",
"name": "Pluvicto",
"prescribingInfo": "https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"sameAs": [
"https://en.wikipedia.org/wiki/Lu-PSMA-617",
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf",
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://www.cancer.org/cancer/types/prostate-cancer/treating/radiation-therapy.html",
"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb973a8d-7fea-4a7a-963f-2a8e67a46e55"
],
"warning": [
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"low level of blood cell counts",
"tiredness or weakness",
"pale skin",
"shortness of breath",
"bleeding or bruising",
"kidney problems",
"pregnancy complications",
"infertility",
"headache",
"tiredness",
"dry mouth",
"nausea",
"appetite loss",
"join pain",
"constipation",
"back pain"
],
"mechanismOfAction": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#mechanismOfAction",
"dosageForm": "Injection",
"availableStrength": {
"@type": "drugStrength",
"activeIngredient": "Lutetium Lu 177 vipivotide tetraxetan",
"sameAs": [
"https://en.wikipedia.org/wiki/Lu-PSMA-617",
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf",
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://medlineplus.gov/druginfo/meds/a622063.html",
"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/lutetium-lu-177-vipivotide-tetraxetan"
],
"strengthUnit": "mCl",
"strengthValue": "200.00"
},
"identifier": {
"@type": "PropertyValue",
"name": "NDC",
"description": "US National Drug Codes",
"sameAs": [
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb973a8d-7fea-4a7a-963f-2a8e67a46e55",
"https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/69488-0010/",
"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication"
],
"value": "69488-0010-61"
},
"doseSchedule": {
"@type": "doseSchedule",
"@id": "https://us.pluvicto.com/about-pluvicto/what-to-expect-with-pluvicto-treatment#doseSchedule",
"doseUnit": "mCl",
"doseValue": "200.00",
"frequency": "Consult Physician",
"description": "Refer to the Full Prescribing Information for the recommended dosage. The recommended PLUVICTO dosage is one dose taken intraveneously every six weeks for up to six treatment cycles. "
},
"offers": {
"@type": "Offer",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto",
"availability": "LimitedAvailability",
"image": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/psma617_pluvicto_r_rgb_us-2.jpg",
"priceValidUntil": "2025-12-31",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto",
"price": "50164.84",
"priceCurrency": "USD"
}
}
}
}
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /about-pluvicto/how-pluvicto-works/ | 0 | 0 |
| /treatment-center-locator/ | 0 | 0 |
| /pluvicto-pulse/ | 1 | 0 |
This page presents a snapshot of public data from Novartis, captured on May 30, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Novartis: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://pluvicto.com to view the most current version of its content and see directly what this company is about and what it offers.